Lexicon Pharmaceuticals (LXRX) Stock Statistics & Valuation Metrics

Lexicon Pharmaceuticals has a market cap or net worth of $716.02M. The enterprise value is $743.93M.

Lexicon Pharmaceuticals has 423,680,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexicon Pharmaceuticals’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -28.71%.

The current PE Ratio of Lexicon Pharmaceuticals is ―. Lexicon Pharmaceuticals’s PEG ratio is 0.11.

In the last 12 months, Lexicon Pharmaceuticals had revenue of 49.80M and earned -50.34M in profits. Earnings per share was -0.14.

In the last 12 months, operating cash flow was -67.85M and capital expenditures 0.00, giving a free cash flow of -67.85M billion.

Lexicon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Lexicon Pharmaceuticals upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).

Lexicon Pharmaceuticals as a current ratio of 4.88, with Debt / Equity ratio of 57.87%

In the past 12 months, Lexicon Pharmaceuticals has paid 0.00 in taxes.

Lexicon Pharmaceuticals EV to EBITDA ratio is -9.22, with an EV/FCF ratio of -6.56.

Lexicon Pharmaceuticals has $96.23M in cash and marketable securities with $62.24M in debt, giving a net cash position of $33.99M billion.

Gross margin is 98.86%, with operating margin of -98.21%, and net profit margin of -101.08%.

The average price target for Lexicon Pharmaceuticals is $3.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy